LentiArray™ CRISPR Negative Control Lentivirus, human, non-targeting
Product Image
Citations & References (1)
Invitrogen™

LentiArray™ CRISPR Negative Control Lentivirus, human, non-targeting

Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative ControlRead more
Have Questions?
Catalog NumberQuantity
A32062100 μL
Catalog number A32062
Price (CNY)
4,165.00
Each
Add to cart
Quantity:
100 μL
Price (CNY)
4,165.00
Each
Add to cart
Negative control gRNAs are essential in screening applications for setting thresholds for hit determination. The Invitrogen™ LentiArray™ CRISPR Negative Control Lentivirus, Human Scrambled, contains a gRNA sequence with no sequence homology to any region of the human genome.
For Research Use Only. Not for use in diagnostic procedures.
Specifications
Control TypeNon-targeting negative control
Delivery TypeLentiviral
For Use With (Application)CRISPR gene knockout
Product LineLentiArray
Product TypeCRISPR Negative Control Lentivirus
Quantity100 μL
Shipping ConditionDry Ice
PromoterU6
SpeciesHuman
Transfection TechniqueLentiviral transduction
Unit SizeEach
Contents & Storage
1 x 100 μL. Store at -68 to -85°C.

Citations & References (1)

Citations & References
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Authors:Sredni ST, Suzuki M, Yang JP, Topczewski J, Bailey AW, Gokirmak T, Gross JN, de Andrade A, Kondo A, Piper DR, Tomita T
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific ... More